Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers von Quintela-Fandino, M., Manso Sànchez, L.M., Holgado Martín, E., Moreno, M.C., Morales Murillo, S., Bermejo De Las Heras, B., Malon Gimenez, D., Colomer Bosch, R., Gonzalez Cortijo, L., Hornedo, J., Mouron, S., Muñoz, M., Escudero, S., Blanco, R., Mañes, S.

Volltext

1195P Neuroendocrine Tumors (NETs): How Big Data (BD) techniques applied to Electronic Health Records (EHR) can improve our understanding of this patient population von Hernando, J., Salva, J. Fuster, Balsa, J.A., Gimenez, D. Malon, Grandoulier, A-S., Courteval, C., Valdivieso, J., Gómez, J.J. Díez

Volltext

1704P Clinical benefit of cancer drugs approved by the US food and drug administration based on appropriateness of control arm and its change over time von Molto, C., Restrepo, A.P., Templeton, A.J., Tibau, A., Mittal, A., Tamimi, F.T., Malon Gimenez, D., Amir, E.

Volltext

1877P Adverse effects (AEs) of trastuzumab deruxtecan (T-DXd) in solid tumours: A meta-analysis von Pathak, N., Di Iorio, M.R., Savill, J., Berner Wygoda, Y., Malon Gimenez, D., Li, M., Molto Valiente, C., Nadler, M., Mittal, A., Amir, E.

Volltext

258P Correlation between pathological complete response (pCR) following neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) with or without pertuzumab (TCHP) and PAM50 subtype... von Muiño, C. Bueno, Diaz-Guardamino, I. Echavarria, Alvarez, E., Gilarranz, Y. Jerez, Lopez, B. Herrero, Del Monte, M., Massarrah, T., Cebollero, M., Nevado, M., Barrio, P.D.L.M. de la Morena, Ayala de la Pena, F., Saenz, J.Á. García, Anton, F. Moreno, Rodriguez, A., Verduguez, T. Quintanar, Gimenez, D. Malon, Garcia, A.I. Ballesteros, Bañón, D., Lopez-Tarruella Cobo, S., Jimenez, M. Martin

Volltext

95P PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study von Pascual, T., Bermejo De Las Heras, B., Martinez, N., Oliveira, M., Pernas Simon, S., Lopez Lopez, R., Ruiz Cabrero, I., Alarcon, J.D., Martinez De Dueñas, E., Malon Gimenez, D., Gonzalez Cao, M., Manso Sanchez, L.M., Morales Murillo, S., Lopez de Ceballos, H., Cortés, J., Llombart Cussac, A., Prat, A.

Volltext

72OAddition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers von Quintela-Fandino, M, Manso Sànchez, L M, Holgado Martín, E, Moreno, M C, Morales Murillo, S, Bermejo De Las Heras, B, Malon Gimenez, D, Colomer Bosch, R, Gonzalez Cortijo, L, Hornedo, J, Mouron, S, Muñoz, M, Escudero, S, Blanco, R, Mañes, S

Volltext

P-238 Real-life data on the use of FLOT4 and CROSS for patients with esophageal, gastric or gastroesophageal junction adenocarcinoma von López, I. Solana, Abad, D. Gutierrez, De Torres Olombrada, M., Moreno, E. Martínez, Martel, I. Juez, Fernández de Soignie, A. Martín, de Zea Luque, C., Baños, N. Sánchez, Martínez, F. Escalona, Vila, B. Losada, Gonzalez, M. Pantin, Lajusticia, L. Rodriguez, Gimenez, D. Malón, Munarriz, B. Jiménez, Martínez, J. Guerra

Volltext

Posterior reversible encephalopathy syndrome associated to chemotherapy. Gemcitabine as the causative agent von Sanchez-Cendra, C, Malon-Gimenez, D, Guerra-Martinez, J A, Calzas-Rodriguez, J, Anton-Pascual, B, Olmo-Sanchez, A

Volltext

Rare site of recurrence in metastatic pancreatic cancer: Regarding a case report von Losada Vila, B, De Torres Olombrada, M.V, Gutiérrez Abad, D, Juez Martel, I, Malón Giménez, D, Rodríguez Lajusticia, L, Calzas Rodriguez, J, Guerra Martínez, J.A

Volltext

252P Impact of informative censoring on the interpretation of progression-free survival (PFS) estimates in phase III randomized trials (RCT) in metastatic breast cancer (MBC) von Wygoda, Y. Berner, Giménez, D. Malón, Di Iorio, M.R., Li, M., Savill, J., Valiente, C. Molto, Amir, E.

Volltext

Posterior reversible encephalopathy syndrome associated to chemotherapy. Gemcitabine as the causative agent von Sanchez-Cendra, C, Malon-Gimenez, D, Guerra-Martinez, J A, Calzas-Rodriguez, J, Anton-Pascual, B, Olmo-Sanchez, A

Volltext

Positive basophil activation test following anaphylaxis to pertuzumab and successful treatment with rapid desensitization von González-de-Olano, David, MD, Morgado, Jose M., BSc, Juárez-Guerrero, Raquel, BS, Sánchez-Muñoz, Laura, MD, PhD, Letellez-Fernández, Javier, BS, Malón-Giménez, Diego, MD, Castells, Mariana C., MD, PhD

Volltext